1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

US Sickle Cell Gene Therapy Contracting Demo Attracting Interest From States

 
• By Laura Helbling

The US Medicaid agency says states representing more than 80% of sickle cell patients are interested in a centralized contracting program, but House Republicans want legislation, not administrative interventions, to shape value-based payment for curative therapies.

sickle cell disease
The CMMI centralized contracting program is only focusing on sickle cell disease for now, Fowler said. • Source: Shutterstock

A US Medicaid program to test centralized contracting for sickle cell disease gene therapies has attracted widespread interest from state payors.

Key Takeaways

  • States are interested in a CMS program on centralized contracting for gene therapies treating sickle cell disease.

  • Rep. Brett Guthrie is concerned the program will not let states work together to negotiate prices

The US Center for Medicare and Medicaid Innovation has received letters of intent from “a majority of states that represent about 80% of patients with sickle cell disease,” CMMI Director Elizabeth Fowler said at a recent House Energy and Commerce/Health Subcommittee hearing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

More from Government Payers